

Influenza and RSV in Adults

Kansas City Southwest Clinical Society

Joel P. McKinsey, M.D., FIDSA Metro Infectious Disease Consultants February 2, 2024








Influenza




- Recurrent <u>epidemics</u> of febrile respiratory disease have occurred every 1 to 3 years for at least the past 400 years
- Epidemics "Seasonal Influenza" occur most years (a result of antigenic drift) From 2010 – 2018 in the U.S.¹
 - 4.3 23 million medical visits yearly
 - 140,000 960,000 influenza-related excess hospitalizations yearly
 - 12,000 79,000 annual deaths
 - 90% of deaths in persons 65 and older²
 - 37% of hospitalizations among persons younger than 65²
 - average annual total economic burden \$11.2 billion³

¹Clinical Infectious Diseases 2019;68(6):e1–47 ²PLOS Medicine 2013; 10(11):e1001558 ³Vaccine 2018;36(27):3960-3966

4










Influenza • <u>Pandemics</u> – global epidem • Pandemics occur when a 'n human transmission enters • The first recorded <u>pandemin</u> influenza occurred in 1580 (32 pandemics have been • The worst pandemic in reco	ew' influenza virus the population <u>c</u> that clearly fits tl recorded since – on a	ly ² (a result of antigenic shift) s capable of human-to- ne description of verage one every ~14 year	
Pandemic	U.S. Deaths	World Deaths	
2009 H1N1	12,000	284,000	
1968-69 H3N2 "Hong Kong Flu"	34,000	1 Million	
1957-58 H2N2 "Asian Flu"	70,000	2 Million	
1918-19 H1N1 "Spanish Flu"	>550,000 U.S. population was ~1/3 of current #	20-50 Million	


²Emerging Infectious Diseases 12(1):15, 2006

Nandell, Principles and Practice of Infectious Diseases

7

Pandemic Influenza A Strains Become the Seasonal Influenza Strains Historical circulation of influenza viruses in the last century 1920 1930 1940 1950 1960 1970 1980 1990 2000 2010 2020 A(H1N1)1977 A(H1N1)1918 A(H1N1)2009 A(H2N2) A(H3N2) B/Victoria B/Yamagata B/Lee Nature Communications (2022) 13:1721





Seasonal Influenza Clinical Course

- Incubation period 1 2 days
- Sudden onset of:
 - Fever, usually lasts 3 days, up to 8
 - Chills, Body aches, Sore throat
 - Non-productive cough, Runny nose, Headache
 - Emesis and diarrhea (more common in children)
- Viral pneumonia uncommon
- Low death rate except in the elderly
- High attack rate in those living in close proximity



12 (46

9 (35) 8 (31)


lgia r ≥37.8°C

NOTE. ARI o

5 (28) 5 (28)

6 (33) 8 (44)

J Infect Dis 2010 May; 201(10): 1509–1516





Seasonal Influenza Clinical Course




· Most people recover from uncomplicated influenza


- Complications resulting in severe illness and death can occur, particularly among:
 - very young children
 - older adults
 - · pregnant and postpartum women within 2 weeks of delivery
 - people with certain chronic medical conditions including chronic pulmonary, cardiac, and neurologic disorders, and metabolic disease

 - · those who are immunocompromised

Clinical Infectious Diseases 2019;68(6):e1-47









Which Influenza Test is Recommended?


• Outpatients:

16

- Rapid influenza molecular assays are recommended over rapid influenza antigen detection tests
- Hospitalized patients: lospitalized patients: • RT-PCR or other molecular assays are recommended • Devidenting which is a start of the start of

 - Rapid antigen detection tests are not recommended
 molecular assays are not available
 follow-up testing with RT-PCR or other molecular assays should be performed
 to confirm negative rapid antigen results
 Immunocompromised patients: Multiplex RT-PCR assays targeting a panel of
 respiratory pathogens, including influenza viruses are recommended RT-PCR on lower respiratory tract specimen if nasopharyngeal PCR is negative (10-19% in intubated patients)

Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza' Clinical Infectious Diseases 2019;68(6):e1–47



Four an	ntivirals are av	ailable to treat influenza:		
illness		efficacy and are FDA-approve ients with uncomplicated infl		days of
	Antiviral Drug	Route of Administration	Recommended Ages for Tr	eatment COST
ſ	Oseltamivir	Oral (twice daily x 5d)	All ages	~\$25-70*
	Zanamivir	Inhaled (twice daily x 5d)	≥7 years	~\$70*
L	Peramivir	Intravenous (single infusion)	≥6 months	~\$1000*
	Baloxavir	Oral (single dose)	≥5 years (otherwise health ≥12 years (high-risk)	y) _{~\$170*}
	ependent endonuclea		C.gov * per	Dr. Google 1/20



Influenza Treatment Summary For Adults





 Treatment started within 36 hours of symptom onset reduced illness duration by 25.2 hours and reduced the risk of lower respiratory tract complications by 44% Single-dose baloxavir had similar median time to alleviation

Special Populations


- Pregnant women and up to two weeks postpartum
 Oseltamivir is recommended (lack of data for others)
- Immunocompromised patients
 Baloxavir is not recommended (risk of resistance emergence due to prolonged viral replication)
- Hospitalized patients
 Antiviral treatments recommended ASAP even if beyond 48 hours from symptom onset
 Inhaled zanamivir and oral baloxavir are not recommended (lack of data)
- Critically ill patients
 Optimal duration of oseltamivir is unclear
- https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm

19









Trade name (manufacturer)	Presentation	Age indication	µg HA (IIV4s and RIV4) or virus count (LAIV4) for each vaccine virus (per dose)	Route	Mercury (from thimero if present) µg/0.5 mL	sal,
IIV4 (standard-dose, egg-based vacc	ines [†])	0.0 1000.0	1000 C	-		_
Afluria Quadrivalent	0.5-mL PF55	23 yrs ⁶	15 µg/0.5 mL	IMT		
(Segirus)	5.0-mL MDV ⁶	26 mos ⁵ (needle and syringe) 18 through 64 yrs (jet injector)	7.5 µg/0.25 mL 15 µg/0.5 mL	IM	24.5	
Fluarix Quadrivalent (GlaxoSmithKline)	0.5-mL PFS	≥6 mos	15 µg/0.5 mL	INS	-	
FluLaval Quadrivalent (GlaxoSmithKline)	0.5-mL PFS	≥6 mos	15 µg/0.5 mL	IWe	-	
Fluzone Quadrivalent	0.5-mL PFS ^{tt}	≥6 mostt	15 µg/0.5 mL	IM ⁴		
(Sanofi Pasteur)	0.5-mL SDV ^{††}	>6 mos ^{††}	15 µg/0.5 mL	IM [®]	-	
	5.0-mL MDV ⁺⁺	≥6 mos ^{††}	7.5 μg/0.25 mL 15 μg/0.5 mL	IMS	25.0	
ccllV4 (standard-dose, cell culture-b	ased vaccine)					
Flucelvax Quadrivalent	0.5-mL PFS	≥6 mos	15 µg/0.5 mL	IMS		
(Segirus)	5.0-mL MDV	≥6 mos	15 µg/0.5 mL	IMT	25.0	
HD-IIV4 (high-dose, egg-based vacc	ine [†])					
Fluzone High-Dose Quadrivalent (Sanofi Pasteur)	0.7-mL PFS	≥65 yrs	60 µg/0.7 mL	IM ⁴	-	
allV4 (standard-dose, egg-based vac	cine [†] with MF59 adjuvant)					
Ruad Quadrivalent (Segirus)	0.5-mL PFS	≥65 yrs	15 µg/0.5 mL	IMS		
RIV4 (recombinant HA vaccine) Flublok Quadrivalent (Sanofi Pasteur)	0.5-mL PFS	≥18 yrs	45 µg/0.5 mL	IM ⁴	-	5 types 9 optior
LAIV4 (egg-based vaccine [†])						- ···
FluMist Quadrivalent (AstraZeneca)	0.2-mL prefilled single-use intranasal sprayer	2 through 49 yrs	10 ^{6.5-7.5} fluorescent focus units/0.2 mL	NAS	100	9 optior


23

Flu Shot – What to Do • Use what you have, try to vaccinate everyone >6 months old • 65 and over: high-dose or adjuvant Concern about egg allergy: cell-based or recombinant (since 2016 egg allergies are no longer considered a contraindication to flu vaccine)



- Concern about thimerosal: single dose (Data from many studies show no evidence of harm caused by the low doses of thimerosal in vaccines. Studies reveal no link between thimerosal and autism.)
- FluMist (nasal spray) available but injection preferred





Flu Vaccine Effectiveness • Varies year to year During the six influenza seasons from 2010–11 through 2015–16, influenza vaccination prevented an estimated • 1.6–6.7 million illnesses 790,000–3.1 million outpatient medical visits 39,000–87,000 hospitalizations and 3,000–10,000 respiratory and circulatory deaths <u>Average PER SEASON</u> During the severe 2017–18 influenza season, notable for an unusually long duration of widespread high influenza activity, flu vaccine is estimated to have prevented 7.1 million illnesses, 3.7 million medical visits, 109,000 hospitalizations, and 8,000 deaths, despite an overall estimated vaccine effectiveness of 38%

MMWR 68(3):1-21, August 23, 2019





Respiratory Syncytial Virus




• In children:

- RSV is the most common cause of bronchiolitis and pneumonia in children under 12 months of age
 In the U.S. there are between 75,000 and 125,000 children hospitalized each year due to complications of RSV infection
- Est. globally there are 64 million cases of RSV annually that result in 253,500 deaths
- Almost all children will have had an RSV infection by their second birthday
- In adults:
 - RSV is associated with up to 12% of medically attended acute respiratory illnesses
 - <1% require hospitalization
 - RSV is the third most commonly identified viral cause among respiratory viruses resulting in hospitalization (pre-COVID-19 pandemic)


J Virology July 2014 88(13): 7602–7617 CDC.gov PLoS ONE 2017 12(8): e0182321 Influenza Other Resp Viruses 2022;16:1133–1140

28







- Reinfection can occur within two months of last infection.
- Older adults have weaker IFNy responses to RSV than younger adults, likely making them more susceptible to infection and to severe infection.













CDC.gov







Study of ~500	e of RSV in Older Adults 20 Episodes of Illness in <u>Adults >65</u> ontinents in the Northern Hemisphere, 2008-10 (before COVID-19)
 RSV was the third leading vi <u>'Influenza-Like Illness'</u> (ILI) 	ral cause of moderate-to-severe*
> Influenza	37.2%
Enterovirus/Rhinovirus	25.6%
> RSV	12.8%
Coronavirus	10.0% [pre-pandemic]
> Human Metapneumovirus	10.0%
> Parainfluenza	7.5%
about twice as common than ho	ive moderate-to-severe ILI episodes (19.5%) was spitalization among episodes positive for any re common compared to influenza A (3.8%)
*defined as ILI with pneumonia, hospitalization	n, or maximum daily influenza symptom severity score (ISS) >2
J Infectious Diseases 2014 Jun 15; 209(12): 1873–1881	

























RSV Treatment in Adults

- For most adults, treatment is supportive
- For those with lower tract infection who present with cough and wheezing, bronchodilators may result in symptom relief, particularly if the patient has underlying reactive airway disease
- Treatment in immunocompromised patients has not been well studied and the optimal approach is uncertain
 - Ribavirin (oral vs. inhaled) and IVIG can be used in those who are severely immunocompromised, such as hematopoietic cell and lung-transplant recipients and selected persons with leukemia


Clinical Infectious Diseases 2013;56(2):258-66







































Influenza and RSV in Adults

Kansas City Southwest Clinical Society

Joel P. McKinsey, M.D., FIDSA Metro Infectious Disease Consultants February 2, 2024

